Antidepressant-like effect of trans-resveratrol: Involvement of serotonin and noradrenaline system

European Neuropsychopharmacology

Volumn 20, Issue 6, 2010, Pages 405-413

  Xu, Ying ^a   Wang, Zhichao ^b   You, Wenting ^c   Zhang, Xiuhua ^c   Li, Shan ^c   Barish, Philip A ^a   Vernon, Matthew M ^a   Du, Xia ^c   Li, Gaowen ^c   Pan, Jianchun ^c   Ogle, William O ^a  

^a University of Florida   (United States)

^b Beijing Haidian Hospital   (China)

^c WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Forced swimming; MAO; Noradrenaline; Serotonin; Tail suspension; Trans Resveratrol

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; BRAIN MONOAMINE; FLUOXETINE; IMIPRAMINE; MOCLOBEMIDE; NORADRENALIN; RESVERATROL; SEROTONIN;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFECT; ENZYME INHIBITION; FEEDING; FRONTAL CORTEX; HIPPOCAMPUS; HOPELESSNESS; HYPOTHERMIA; IMMOBILIZATION; LOCOMOTION; MALE; MOUSE; NEUROCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIOXIDANTS; APOMORPHINE; BEHAVIOR, ANIMAL; BRAIN CHEMISTRY; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FENCLONINE; HINDLIMB SUSPENSION; HYPOTHERMIA; MALE; MICE; MICE, INBRED ICR; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; MOTOR ACTIVITY; NOREPINEPHRINE; SEROTONIN; STEREOTYPED BEHAVIOR; STILBENES; SWIMMING;

EID: 77952543441     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2010.02.013     Document Type: Article

References (42)

1. Bai Y., Mao Q.Q., Qin J., Zheng X.Y., Wang Y.B., Yang K., Shen H.F., Xie L.P. Resveratrol induces apoptosis and cell cycle arrest of human T24 bladder cancer cells in vitro and inhibits tumor growth in vivo. Cancer Sci. 2010, 101:488-493.
2. Berton O., Nestler E.J. New approaches to antidepressant drug discovery: beyond monoamines. Nat. Rev. Neurosci. 2006, 7:137-151.
3. Bhutani M.K., Bishnoi M., Kulkarni S.K. Anti-depressant like effect of curcumin and its combination with piperine in unpredictable chronic stress-induced behavioral, biochemical and neurochemical changes. Pharmacol. Biochem. Behav. 2009, 92:39-43.
4. Blier P., De Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol. Sci. 1994, 15:220-226.
5. Bortolato M., Chen K., Shih J.C. Monoamine oxidase inactivation: from pathophysiology to therapeutics. Adv. Drug Deliv. Rev. 2008, 60:1527-1533.
6. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal. Biochem. 1976, 72:248-254.
7. Butterweck V., Bockers T., Korte B., Bittkowski W., Winterhoff H. Long-term effects of St. John's wort and hypericin on monoamine levels in rat hypothalamus and hippocampus. Brain Res. 2002, 930:21-29.
8. Chen L.W., Wang Y.Q., Wei L.C., Shi M., Chan Y.S. Chinese herbs and herbal extracts for neuroprotection of dopaminergic neurons and potential therapeutic treatment of Parkinson's disease. CNS Neurol. Disord. Drug Targets 2007, 6:273-281.
9. Dasgupta B., Milbrandt J. Resveratrol stimulates AMP kinase activity in neurons. PNAS 2007, 104:7217-7222.
10. Deniker P. The search for new antidepressants and related drugs. Monoamine Oxidase and Diseases, Prospects for Therapy with Reversible Inhibitors 1984, 3-8. Academic Press, New York, NY. K.F. Tipton, D. Dostert, M.S. Benedetti (Eds.).
11. Dhingra D., Sharma A. Antidepressant-like activity of Glycyrrhiza glabra L. in mouse models of immobility tests. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006, 30:449-454.
12. Dremencov E., Mansari M.E.I., Blier P. Brain norepinephrine system as a target for antidepressant and mood stabilizing medications. Curr. Drug Targets 2009, 10:1061-1068.
13. Eren I., Naziroglu M., Demirdas A. Protective effects of lamotrigine, aripiprazole and escitalopram on depression-induced oxidative stress in rat brain. Neurochem. Res. 2007, 32:1188-1195.
14. Franklin K.B.J., Paxinos G. The Mouse Brain in Stereotaxic Coordinates 1997, Academic Press, San Diego, CA.
15. Guiard B.P., Mansari M.E.I., Blier P. Prospect of a dopamine contribution in the next generation of antidepressant drugs: the triple reuptake inhibitors. Curr. Drug Targets 2009, 10:1069-1084.
16. Herken H., Gurel A., Selek S., Armutcu F., Ozen M.E., Bulut M., Kap O., Yumru M., Savas H.A., Akyol O. Adenosine deaminase, nitric oxide, superoxide dismutase, and xanthine oxidase in patients with major depression: impact of antidepressant treatment. Arch. Med. Res. 2007, 38:247-252.
17. Kulkarni S.K., Bhutani M.K., Bishnoi M. Antidepressant activity of curcumin: involvement of serotonin and dopamine system. Psychopharmacology 2008, 201:435-442.
18. Kumar A., Naidu P.S., Seghal N., Padi S.S. Neuroprotective effects of resveratrol against intracerebroventricular colchicine-induced cognitive impairment and oxidative stress in rats. Pharmacology 2007, 79:17-26.
19. Langer S.Z. Presynaptic receptors and their role in the regulation of transmitter release. Br. J. Pharmacol. 1977, 60:481-497.
20. Mazzio E.A., Harris N., Soliman K.F. Food constituents attenuate monoamine oxidase activity and peroxide levels in C6 astrocyte cells. Planta Med. 1998, 64(7):603-606.
21. Nitta A., Furukawa Y., Hayashi K., Hiramatsu M., Kameyama T., Nabeshima T. Denervation of dopaminergic neurons with 6-hydroxydopamine increases nerve growth factor content in rat brain. Neurosci. Lett. 1992, 144:152.
22. Pineyro G., Blier P. Autoregulation of serotonin neurons: role in antidepressant drug action. Pharmacol. Rev. 1999, 51:533-591.
23. Porsolt R.D., Pichon M.L.E., Jalfre M. Behavioral despair in mice: a primary screening test for antidepressant. Arch. Int. Pharmacodyn. Ther. 1977, 229:327-336.
24. Porsolt R.D., Bertin A., Jalfre M. Behavioural despair in rats and mice: strain differences and the effects of imipramine. Eur. J. Pharmacol. 1978, 51:291-294.
25. Puech A.J., Chermat R., Poncelet M., Doare L., Simon P. Antagonism of hypothermia and behavioral response to apomorphine: a simple, rapid and discriminating test for screening antidepressants and neuroleptics. Psychopharmacology 1981, 75:84-91.
26. Ranney A., Petro M.S. Resveratrol protects spatial learning in middle-aged C57BL/6 mice from effects of ethanol. Behav. Pharmacol. 2009, 20:330-336.
27. Redrobe J.P., Bourin M., Colombel M.C., Baker G.B. Psychopharmacological profile of the selective serotonin reuptake inhibitor, paroxetine: implication of noradrenergic and serotonergic mechanisms. J. Psychopharmacol. 1998, 12:348-355.
28. Redrobe J.P., Dumont Y., Fournier A., Baker G.B., Quirion R. Role of serotonin (5-HT) in the antidepressant-like properties of neuropeptide Y (NYP) in the mouse forced swim test. Peptides 2005, 26:1394-1400.
29. Sale S., Verschoyle R.D., Boocock D., Jones D.J.L., Wilsher N., Ruparelia K.C., Potter G.A., Farmer P.B., Steward W.P., Gescher A.J. Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3, 4, 5, 4'-tetramethoxystilbene. Br. J. Cancer 2004, 90:736-744.
30. Skaer T.L., Sclar D.A., Robison L.M. Trends in prescriptions for antidepressant pharmacotherapy among US children and adolescents diagnosed with depression, 1990 through 2001: an assessment of accordance with treatment recommendations from the American Academy of Child and Adolescent Psychiatry. Clin. Ther. 2009, 31:1478-1487.
31. Stahl S.M., Felker A. Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants. CNS Spectr. 2008, 13:855-870.
32. Steru L., Chermat R., Thierry B., Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 1985, 85:367-370.
33. Thachil A.F., Mohan R., Bhugra D. The evidence base of complementary and alternative therapies in depression. J. Affect. Disord. 2007, 97:23-35.
34. Tredici G., Miloso M., Nicolini G., Galbiati S., Cavaletti G., Bertelli A. Resveratrol, map kinases and neuronal cells: might wine be a neuroprotectant?. Drugs Exp. Clin. Res. 1999, 25:99-103.
35. Viana A., Rego J.C.D., Poser G.V., Ferraz A., Heckler A.R., Costentin J., Rates S.M.K. The antidepressant-like effect of Hypericum caprifoliatum Cham & Schlecht on forced swimming test results from an inhibition of neuronal monoamine uptake. Neuropharmacology 2005, 49:1042-1052.
36. Vitrac X., Desmouliere A., Brouillaud B., Krisa S., Deffieux G., Barthe N., Rosenbaum J., Merillon J.M. Distribution of [14C]-trans-resveratrol, a cancer chemopreventive polyphenol, in mouse tissues after oral administration. Life Sci. 2003, 72:2219-2233.
37. 2 receptors. Eur. J. Pharmacol. 2008, 578:43-50.
38. Xu Y., Ku B.S., Yao H.Y., Lin Y.H., Ma X., Zhang Y.H., Li X.J. The effects of curcumin on depressive-like behaviors in mice. Eur. J. Pharmacol. 2005, 518:40-46.
39. Xu Y., Ku B.S., Yao H.Y., Lin Y.H., Ma X., Zhang Y.H., Li X.J. Antidepressant effects of curcumin in the forced swim test and olfactory bulbectomy models of depression in rats. Pharmacol. Biochem. Behav. 2005, 82:200-206.
40. Xu Y., Ku B.S., Lu T., Yao H.Y., Jiang W.G., Ma X., Li X.J. Curcumin reverses the effects of chronic stress on behavior, the HPA axis, BDNF expression and phosphorylation of CREB. Brain Res. 2006, 1122:56-64.
41. Yáñez M., Fraiz N., Cano E., Orallo F. Inhibitory effects of cis- and trans-resveratrol on noradrenaline and 5-hydroxytryptamine uptake and on monoamine oxidase activity. Biochem. Biophys. Res. Commun. 2006, 344:688-695.
42. Yáñez M., Fraiz N., Cano E., Orallo F. (-)-Trans-epsilon-viniferin, a polyphenol present in wines, is an inhibitor of noradrenaline and 5-hydroxytryptamine uptake and of monoamine oxidase activity. Eur. J. Pharmacol. 2006, 542:54-60.